











2. Halder RM, Grimes PE, McLaurin CL, et al. Incidence of common dermatoses in a predominantly black dermatologic practice. *Cutis*. 1983;32:388, 390.
3. Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: a comparative practice survey. *Cutis*. 2007;80:387-394.
4. Davis SA, Narahari S, Feldman SR, et al. Top dermatologic conditions in patients of color: an analysis of nationally representative data. *J Drugs Dermatol*. 2012;11:466-473.
5. Perkins AC, Cheng CE, Hillebrand GG, et al. Comparison of the epidemiology of acne vulgaris among Caucasians, Asian, Continental Indian and African American women. *J Eur Acad Dermatol Venereol*. 2011;25:1054-1060.
6. Taylor SC, Cook-Bolden F, Rahman Z, et al. Acne vulgaris in skin of color. *J Am Acad Dermatol*. 2002;46(2 suppl):S98-S106.
7. Davis EC, Callender VD. A review of acne in ethnic skin: pathogenesis, clinical manifestations, and management strategies. *J Clin Aesthet Dermatol*. 2010;3:24-38.
8. Halder RM, Holmes YC, Bridgeman-Shah S, et al. A clinicohistologic study of acne vulgaris in black females (abstract). *J Invest Dermatol*. 1996;106:888.
9. Plewig G, Fulton JE, Kligman AM. Pomade acne. *Arch Dermatol*. 1970;101:580-584.
10. Kligman AM, Mills OH. Acne cosmetica. *Arch Dermatol*. 1972;106:893-897.
11. Halder RM, Brooks HL, Callender VD. Acne in ethnic skin. *Dermatol Clin*. 2003;21:609-615.
12. Callender VD. Acne in ethnic skin: special considerations for therapy. *Dermatol Ther*. 2004;17:184-195.
13. Winhoven SM. Postinflammatory hyperpigmentation in an Asian patient: a dramatic response to oral isotretinoin (13-cis-retinoic acid). *Br J Med*. 2005;152:368-403.
14. Sarkar R, Bansal S, Garg VK. Chemical peels for melasma in dark-skinned patients. *J Cutan Aesthet Surg*. 2012;5:247-253.
15. Alexis AF, Coley MK, Nijhawan RL, et al. Nonablative fractional laser resurfacing for acne scarring in patients with Fitzpatrick skin phototypes IV-VI. *Dermatol Surg*. 2016;42:392-402.
16. Culp B, Scheinfeld N. Rosacea: a review. *P T*. 2009;34:38-45.
17. Al-Dabagh A, Davis SA, McMichael AJ, et al. Rosacea in skin of color: not a rare diagnosis. *Dermatol Online J*. 2014;20. pii:13030/qt1mv9r0ss.
18. Del Rosso JQ. Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema. *J Clin Aesthet Dermatol*. 2012;5:16-25.
19. Jackson JM, Knuckles M, Minni JP, et al. The role of brimonidine tartrate gel in the treatment of rosacea. *Clin Cosmet Investig Dermatol*. 2015;23:529-538.
20. Patel NU, Shukla S, Zaki J, et al. Oxymetazoline hydrochloride cream for facial erythema associated with rosacea. *Expert Rev Clin Pharmacol*. 2017;10:104954.
21. Weinkle AP, Doktor V, Emer J. Update on the management of rosacea. *Clin Cosmet Investig Dermatol*. 2015;8:159-177.
22. Grimes PE. Skin and hair cosmetic issues in women of color. *Dermatol Clin*. 2000;19:659-665.
23. Taylor A, Pawaskar M, Taylor SL, et al. Prevalence of pigmentary disorders and their impact on quality of life: a prospective cohort study. *J Cosmet Dermatol*. 2008;7:164-168.
24. Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. *J Clin Aesthet Dermatol*. 2010;3:20-31.
25. Grimes PE. Melasma: etiologic and therapeutic considerations. *Arch Dermatol*. 1995;131:1453-1457.
26. Handel AC, Miot LD, Miot HA. Melasma: a clinical and epidemiological review. *An Bras Dermatol*. 2014;89:771-782.
27. Callender VD, Reid SD, Obayan O, et al. Diagnostic clues to frontal fibrosing alopecia in patients of African descent. *J Clin Aesthet Dermatol*. 2016;9:45-51.
28. Narang T, Sawatkar GU, Kumaran MS, et al. Minocycline for recurrent and/or chronic erythema nodosum leprosum. *JAMA Dermatol*. 2015;151:1026-1028.
29. Boyer M, Katta R, Markus R. Diltiazem-induced photodistributed hyperpigmentation. *Dermatol Online J*. 2003;9:10.
30. Pandya AG, Guevara IL. Disorders of hyperpigmentation. *Dermatol Clin*. 2000;18:91-98.
31. Taylor SC, Torok H, Jones T, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. *Cutis*. 2003;72:67-72.
32. Bulengo-Ransby SM. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. *N Engl J Med*. 1993;328:1438-1443.
33. Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study. *Cutis*. 2006;77:45-50.
34. Jacyk WK. Adapalene in the treatment of African patients. *J Eur Acad Dermatol Venereol*. 2001;15(suppl 3):37-42.
35. Kirik LH. Efficacy and safety of azelaic acid (Aza) gel 15% in the treatment of postinflammatory hyperpigmentation and acne: a 16-week, baseline-controlled study. *J Drugs Dermatol*. 2011;10:586-590.
36. Lee HC, Thng TG, Goh CL. Oral tranexamic acid (TA) in the treatment of melasma. *J Am Acad Dermatol*. 2016;75:385-392.
37. Kindred C, Okereke U, Callender VD. Skin-lightening agents: an overview of prescription, office-dispensed, and over-the-counter products. *Cosmet Dermatol*. 2013;26:18-26.
38. Makino ET, Kadoya K, Sigler ML, et al. Development and clinical assessment of a comprehensive product for pigmentation control in multiple ethnic populations. *J Drugs Dermatol*. 2016;15:1562-1570.
39. Halder R, Rodney I, Munhutu M, et al. Evaluation and effectiveness of a photoprotection composition (sunscreen) on subjects of skin of color. *J Am Acad Dermatol*. 2015;72(suppl 1):AB215.
40. Castaneda-Cazares JP, Hernandez-Blanco D, Carlos-Ortega B, et al. Near-visible light and UV photoprotection in the treatment of melasma: a double-blind randomized trial. *Photodermatol Photoimmunol Photomed*. 2014;30:35-42.
41. American Society for Aesthetic Plastic Surgery. 2016 *Cosmetic Surgery National Data Bank Statistics*. <https://www.surgery.org/sites/default/files/ASAPS-Stats2016.pdf>. Accessed November 15, 2017.
42. Burgess CM. Soft tissue augmentation in skin of color: market growth, available fillers and successful techniques. *J Drugs Dermatol*. 2007;6:51-55.
43. Davis EC, Callender VD. Aesthetic dermatology for aging ethnic skin. *Dermatol Surg*. 2011;37:901-917.
44. Grimes PE, Arora S, Minus HR, et al. Dermatitis papulosa nigra. *Cutis*. 1983;32:385-386.
45. Lupo M. Dermatitis papulosa nigra: treatment options. *J Drugs Dermatol*. 2007;6:29-30.
46. Grimes PE, Shabazz D. A four-month randomized, double-blind evaluation of the efficacy of botulinum toxin type A for the treatment of glabellar lines in women with skin types V and VI. *Dermatol Surg*. 2009;35:429-435.
47. Burgess CM, Awosika O. Ethnic and gender considerations in the use of facial injectables: African-American patients. *Plast Reconstr Surg*. 2015;136(5 suppl):28S-31S.
48. Taylor SC, Kelly AP, Lim HW, et al, eds. *Taylor and Kelly's Dermatology for Skin of Color*. 2nd ed. New York, NY: McGraw-Hill Education; 2016.
49. Taylor SC, Burgess CM, Callender VD. Safety of nonanimal stabilized hyaluronic acid dermal fillers in patients with skin of color: a randomized, evaluator-blinded comparative trial. *Dermatol Surg*. 2009;35(suppl 2):1653-1660.
50. Marmur ES, Taylor SC, Grimes PE, et al. Six-month safety results of calcium hydroxylapatite for treatment of nasolabial folds in Fitzpatrick skin types IV to VI. *Dermatol Surg*. 2009;35(suppl 2):1641-1645.
51. Hamilton TK, Burgess CM. Consideration for the use of injectable poly-L-lactic acid in people of color. *J Drugs Dermatol*. 2010;9:451-456.
52. Fabi SG, Goldman MP. Retrospective evaluation of micro-focused ultrasound for lifting and tightening of the face and neck. *Dermatol Surg*. 2014;40:569-575.
53. Harris MO, Sundaram HA. Safety of microfocused ultrasound with visualization in patients with Fitzpatrick skin phototypes III to VI. *JAMA Facial Plast Surg*. 2015;17:355-357.